CoChat
Sign Up
Cited by 1,040

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Advances in drug delivery systems, challenges and future directions

Ezike, Tobechukwu Christian, Okpala, Ugochukwu Solomon, Onoja, Ufedo Lovet, Nwike, Chinenye Princess, Ezeako, Emmanuel Chimeh, Okpara, Osinachi Juliet, Okoroafor, Charles Chinkwere, Eze, Shadrach Chinecherem, Kalu, Onyinyechi Loveth, Odoh, Evaristus Chinonso, Nwadike, Ugochukwu Gideon, Ogbodo, John Onyebuchi, Umeh, Bravo Udochukwu, Ossai, Emmanuel Chekwube, Nwanguma, Bennett Chima·2023·Heliyon
DOI 10.1016/j.heliyon.2023.e17488PMC PMC10320272
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.heliyon.2023.e17488

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Several types of recent drug delivery systems for different therapeutic purposes.
Fig. 1 Several types of recent drug delivery systems for different therapeutic purposes.CC BY-NC-ND · PubMed Central
Fig. 2 Synthetic strategies for RBCM-NPs preparation for antitumor activity. Whole fresh blood is centrifuged and washed multiple times to remove the plasma and other unwanted cells. The resulting pure red blood cells are subjected to hypotonic hemolysis and are used to coat selected nanoparticles which are intravenously injected into the blood to maintain long systemic circulation. The RBCM-NPs permeate the tumor tissue via the EPR effect and finally enter into the tumor cells by endocytosis for therapeutic effect. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2 Synthetic strategies for RBCM-NPs preparation for antitumor activity. Whole fresh blood is centrifuged and washed multiple times to remove the plasma and other unwanted cells. The resulting pure red blood cells are subjected to hypotonic hemolysis and are used to coat selected nanoparticles which are intravenously injected into the blood to maintain long systemic circulation. The RBCM-NPs permeate the tumor tissue via the EPR effect and finally enter into the tumor cells by endocytosis for therapeutic effect. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)CC BY-NC-ND · PubMed Central
Fig. 3 The application of hyaluronic acid-based nanocarriers in cancer treatment. (a) and (b) Direct conjugation of cytotoxic drug with HA or hydrophobic moiety results in self-assembly of nanoparticles (NPs) that can be administered intravenously for cancer cell targeting; (b) HA hydrogel formation using a cationic polymer; (c) Surface coating of NP with HA; (e) Hyaluronic acid-based drug nanocarriers permeate cancerous tissues via EPR effect and binds to the CD44 receptor site to elicit anticancer activity.
Fig. 3 The application of hyaluronic acid-based nanocarriers in cancer treatment. (a) and (b) Direct conjugation of cytotoxic drug with HA or hydrophobic moiety results in self-assembly of nanoparticles (NPs) that can be administered intravenously for cancer cell targeting; (b) HA hydrogel formation using a cationic polymer; (c) Surface coating of NP with HA; (e) Hyaluronic acid-based drug nanocarriers permeate cancerous tissues via EPR effect and binds to the CD44 receptor site to elicit anticancer activity.CC BY-NC-ND · PubMed Central
Fig. 4 Schematic explanation of H-BN nanosheet drug delivery system. H-BN was exfoliated via chemical treatment and functionalized with Au particles resulting in high loading capacity of DOX, a chemotherapy drug which is released in tumor cells by decrease in pH.
Fig. 4 Schematic explanation of H-BN nanosheet drug delivery system. H-BN was exfoliated via chemical treatment and functionalized with Au particles resulting in high loading capacity of DOX, a chemotherapy drug which is released in tumor cells by decrease in pH.CC BY-NC-ND · PubMed Central
Fig. 5 The formation of a Polymeric-Lipid Hybrid Nanoparticle. The Hybrid contains three distinct components which include: A polymeric core that encapsulates both hydrophilic and hydrophobic drugs effectively. A lipid shell that provides biocompatibility and high stability and a lipid-polyethylene glycol (PEG) that is found in the outer part and covered by a lipid layer to provide increased steric stability, prevent immune recognition and increase time for circulation.
Fig. 5 The formation of a Polymeric-Lipid Hybrid Nanoparticle. The Hybrid contains three distinct components which include: A polymeric core that encapsulates both hydrophilic and hydrophobic drugs effectively. A lipid shell that provides biocompatibility and high stability and a lipid-polyethylene glycol (PEG) that is found in the outer part and covered by a lipid layer to provide increased steric stability, prevent immune recognition and increase time for circulation.CC BY-NC-ND · PubMed Central
Fig. 6 Mechanism of Self-emulsification in aqueous environment. SEDDS comprise a mixture drugs, surfactants, oil, stabilizers, and cosolvents. Like conventional emulsification, SEDDS (ionotropic mixture) form (o/w) nano or microemulsion within the gastrointestinal tract with very small energy input.
Fig. 6 Mechanism of Self-emulsification in aqueous environment. SEDDS comprise a mixture drugs, surfactants, oil, stabilizers, and cosolvents. Like conventional emulsification, SEDDS (ionotropic mixture) form (o/w) nano or microemulsion within the gastrointestinal tract with very small energy input.CC BY-NC-ND · PubMed Central
Fig. 7 Schematic representation of MEMS components. Generally, MEMS is made up of mechanical microstructures, microactuators, microsensors, and microelectronics all integrated onto a single silicon chip. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 7 Schematic representation of MEMS components. Generally, MEMS is made up of mechanical microstructures, microactuators, microsensors, and microelectronics all integrated onto a single silicon chip. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 123

  1. Rayaprolu, 2018, Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics, Drug Dev. Ind. Pharm., 44, 1565, 10.1080/03639045.2018.1483392 · DOI
  2. Alqahtani, 2021, Advances in oral drug delivery, Front. Pharmacol., 12, 10.3389/fphar.2021.618411 · DOI
  3. Chauhan, 2022, Recent Advances in Ophthalmic Drug Delivery, 1
  4. Thirunavukkarasu, 2022, Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: a review, Diabetes Res. Clin. Pract., 10.1016/j.diabres.2022.109996 · DOI
  5. Sharma, 2022, Subcutaneous drug delivery: a review of the state-of-the-art modelling and experimental techniques, J. Biomech. Eng.
  6. Misbah Ul Haq, 2021, Rectal drug delivery system: an overview, Clin. Pharmacol. Biopharm., 10
  7. Mahant, 2022, Emerging trends and potential prospects in vaginal drug delivery, Curr. Drug Deliv.
  8. Cho, 2018, Biochemical and Biophysical Research Communications the immunotherapeutic effects of recombinant Bacillus rin resistant to antimicrobial peptides on Calmette-Gu e bladder cancer cells, Biochem. Biophys. Res. Commun.
  9. Palugan, 2021, International Journal of Pharmaceutics : X Intravesical drug delivery approaches for improved therapy of urinary bladder diseases, Int. J. Pharm. X., 3
  10. Keraliya, 2012, Osmotic drug delivery system as a part of modified release dosage form, ISRN Pharm
  11. Mattos, 2017, Biogenic silica nanoparticles loaded with neem bark extract as green, slow-release biocide, 142, 4206
  12. Ding, 2017, A review of drug release mechanisms from nanocarrier systems, Mater. Sci. Eng. C., 76, 1440, 10.1016/j.msec.2017.03.130 · DOI
  13. Danhier, 2015, To exploit the tumor microenvironment : passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Contr. Release, 148, 135, 10.1016/j.jconrel.2010.08.027 · DOI
  14. Patra, 2018, Nano based drug delivery systems : recent developments and future prospects, J. Nanobiotechnol., 1
  15. Malm, 1951, Cellulose acetate phthalate as an enteric coating material, J. Am. Pharm. Assoc. (Scientific Ed.)., 40, 520, 10.1002/jps.3030401014 · DOI
  16. Yun, 2014, Controlled drug delivery systems: the next 30 years, Front. Chem. Sci. Eng., 8, 276, 10.1007/s11705-014-1426-x · DOI
  17. Zhang, 2017, Big data analysis of global advances in pharmaceutics and drug delivery 1980-2014, Drug Discov. Today, 22, 1201, 10.1016/j.drudis.2017.05.012 · DOI
  18. Bangham, 1964, Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope, J. Mol. Biol., 8, 10.1016/S0022-2836(64)80115-7 · DOI
  19. Bangham, 1965, Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol., 13, 10.1016/S0022-2836(65)80093-6 · DOI · Paper page
  20. Birrenbach, 1976, Polymerized micelles and their use as adjuvants in immunology, J. Pharm. Sci., 65, 1763, 10.1002/jps.2600651217 · DOI
  21. Couvreur, 1977, Nanocapsules: a new type of lysosomotropic carrier, FEBS Lett., 84, 323, 10.1016/0014-5793(77)80717-5 · DOI
  22. Park, 2016, Drug delivery of the future: chasing the invisible gorilla, J. Contr. Release, 240, 2, 10.1016/j.jconrel.2015.10.048 · DOI
  23. Ye, 2010, Issues in long-term protein delivery using biodegradable microparticles, J. Control. Release Off. J. Control. Release Soc., 146, 241, 10.1016/j.jconrel.2010.05.011 · DOI · Paper page
  24. Park, 2014, Controlled drug delivery systems: past forward and future back, J. Contr. Release, 190, 3, 10.1016/j.jconrel.2014.03.054 · DOI
  25. Yun, 2015, Controlled drug delivery: historical perspective for the next generation, J. Contr. Release, 219, 2, 10.1016/j.jconrel.2015.10.005 · DOI
  26. Rahman, 2020, Novel drug delivery systems for loading of natural plant extracts and their biomedical applications, Int. J. Nanomed., 15, 2439, 10.2147/IJN.S227805 · DOI
  27. Vincy, 2022, Recent progress in red blood cells-derived particles as novel bioinspired drug delivery systems: challenges and strategies for clinical translation, Front. Chem., 10, 10.3389/fchem.2022.905256 · DOI
  28. Patil, 2019, A review on topical gels as drug delivery system, J. Drug Deliv. Therapeut., 9
  29. Hanley, 2021, Phototheranostics using erythrocyte-based particles, Biomolecules, 11, 10.3390/biom11050729 · DOI
  30. Wang C, 2014, Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer, Adv. Mater., 26, 4794, 10.1002/adma.201400158 · DOI
  31. Jiawei Chen, 2020, Nanoscale delivery system for nutraceuticals: preparation, application, characterization, safety, and future trends, Food Eng. Rev., 12, 14, 10.1007/s12393-019-09208-w · DOI
  32. Zinger, 2021, Biomimetic nano drug delivery carriers for treating cardiovascular diseases, Nanomed. Nanotechnol. Biol. Med., 33, 10.1016/j.nano.2021.102360 · DOI
  33. Gao, 2020, Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer's disease, J. Nanobiotechnol., 18, 71, 10.1186/s12951-020-00626-1 · DOI
  34. Mamo, 2010, Emerging nanotechnology approaches for HIV/AIDS treatment and prevention, Nanomedicine, 5, 269, 10.2217/nnm.10.1 · DOI
  35. Moss, 2013, HIV/AIDS review, Radiol. Technol., 84, 247
  36. Alaniz, 2002, Interaction of CD44 with different forms of hyaluronic acid. Its role in adhesion and migration of tumor cells, Cell Commun. Adhes., 9, 117, 10.1080/15419060214522 · DOI
  37. Kang, 2015, Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment, Acta Pharm. Sin. B., 5, 169, 10.1016/j.apsb.2015.03.001 · DOI
  38. Rizvi, 2018, Applications of nanoparticle systems in drug delivery technology, Saudi Pharmaceut. J., 26, 64, 10.1016/j.jsps.2017.10.012 · DOI
  39. Yu, 2020, Development of a hyaluronic acid-based nanocarrier incorporating doxorubicin and cisplatin as a pH-sensitive and CD44-targeted anti-breast cancer drug delivery system, Front. Pharmacol., 11, 10.3389/fphar.2020.532457 · DOI · Paper page
  40. Jia, 2022, Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: recent advances, Front. Bioeng. Biotechnol., 10, 10.3389/fbioe.2022.990145 · DOI
  41. Huang, 2018, Application of hyaluronic acid as carriers in drug delivery, Drug Deliv., 25, 766, 10.1080/10717544.2018.1450910 · DOI
  42. Sharker, 2019, Hexagonal boron nitrides (white graphene): a promising method for cancer drug delivery, Int. J. Nanomed., 14, 9983, 10.2147/IJN.S205095 · DOI
  43. Weng, 2016, Functionalized hexagonal boron nitride nanomaterials: emerging properties and applications, Chem. Soc. Rev., 45, 3989, 10.1039/C5CS00869G · DOI
  44. Liu, 2019, Functionalized h-BN nanosheets as a theranostic platform for SERS real-time monitoring of MicroRNA and photodynamic therapy, Angew. Chem. Int. Ed. Engl., 58, 7757, 10.1002/anie.201902776 · DOI
  45. Jose, 2018, Polymeric lipid hybrid nanoparticles: properties and therapeutic applications, Crit. Rev. Ther. Drug Carrier Syst., 35, 555, 10.1615/CritRevTherDrugCarrierSyst.2018024751 · DOI
  46. Pérez-Herrero, 2015, Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Fur Pharm. Verfahrenstechnik e.V., 93, 52
  47. Choudhury, 2019, Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting, Int. J. Pharm., 565, 509, 10.1016/j.ijpharm.2019.05.042 · DOI
  48. Rizwanullah, 2020, Polymer-lipid hybrid nanoparticles: a next-generation nanocarrier for targeted treatment of solid tumors, Curr. Pharmaceut. Des., 26, 1206, 10.2174/1381612826666200116150426 · DOI
  49. Mohanty, 2020, Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy, Molecules, 25, 10.3390/molecules25194377 · DOI · Paper page
  50. Pouton, 2006, Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., 29, 278
  51. Savjani, 2012, Drug solubility: importance and enhancement techniques, ISRN Pharm
  52. Vinarov, 2021, Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review, Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., 162
  53. Tang, 2008, Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms, Drug Discov. Today, 13, 606, 10.1016/j.drudis.2008.04.006 · DOI
  54. Rajpoot, 2019, Self-microemulsifying drug-delivery system: ongoing challenges and future ahead, in, 393
  55. Gursoy, 2004, Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs, Biomed. Pharmacother., 58, 173, 10.1016/j.biopha.2004.02.001 · DOI
  56. Mehanna, 2021, Formulation and applications of lipid-based nanovehicles: spotlight on self-emulsifying systems, Adv. Pharmaceut. Bull., 11, 56, 10.34172/apb.2021.006 · DOI
  57. Baloch, 2019, Self-nanoemulsifying drug delivery system (SNEDDS) for improved oral bioavailability of chlorpromazine: in vitro and in vivo evaluation, Medicina (Kaunas), 55
  58. Dokania, 2015, Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead, Drug Deliv., 22, 675, 10.3109/10717544.2014.896058 · DOI
  59. Lokhande, 2018, An update review on recent advancements in multiple emulsion, Int. J. Res. Sci. Innov., 5, 90
  60. Parmar, 2011, Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system, Colloids Surf. B Biointerfaces, 86, 327, 10.1016/j.colsurfb.2011.04.016 · DOI
  61. Rahman, 2013, Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS), Drug Dev. Ind. Pharm., 39, 1, 10.3109/03639045.2012.660949 · DOI
  62. Azmi, 2019, Nanoemulsions: factory for food, pharmaceutical and cosmetics, Processes, 7, 10.3390/pr7090617 · DOI
  63. Rao, 2012, Food-grade microemulsions and nanoemulsions: role of oil phase composition on formation and stability, Food Hydrocolloids, 29, 326, 10.1016/j.foodhyd.2012.04.008 · DOI
  64. Glassman, 2019, Pharmacokinetic and pharmacodynamic properties of drug delivery systems, J. Pharmacol. Exp. Therapeut., 370, 570, 10.1124/jpet.119.257113 · DOI
  65. Tiwari, 2012, Drug delivery systems: an updated review, Int. J. Pharm. Investig., 2, 2, 10.4103/2230-973X.96920 · DOI · Paper page
  66. Vigani, 2020, Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes, Pharmaceutics, 12, 10.3390/pharmaceutics12090859 · DOI
  67. Hua, 2019, Physiological and pharmaceutical considerations for rectal drug formulations, Front. Pharmacol., 10, 1196, 10.3389/fphar.2019.01196 · DOI
  68. Singh, 2017, Stimuli-responsive systems with diverse drug delivery and biomedical applications: recent updates and mechanistic pathways, Crit. Rev. Ther. Drug Carrier Syst., 34, 209, 10.1615/CritRevTherDrugCarrierSyst.2017017284 · DOI
  69. Khule, 2021, A Review: in-situ Gel Drug Delivery System, 9, 2455
  70. Bashir, 2021, An in sight into novel drug delivery system: in situ gels, TANG [HUMANITAS Med
  71. Bashir, 2019, Floating oral in-situ gel: a review, J. Drug Deliv. Therapeut., 9, 442, 10.22270/jddt.v9i2.2372 · DOI
  72. Padhan, 2019, Floating oral in-situ gel, a comprehensive approach of gastro-retentive drug delivery system: a review, Int. J. Pharm. Sci. Res., 10, 4026
  73. Sheshala, 2015, In situ gelling ophthalmic drug delivery system: an overview and its applications., recent pat, Drug Deliv. Formul., 9, 237
  74. Wu, 2019, Research progress of in-situ gelling ophthalmic drug delivery system, Asian J. Pharm. Sci., 14, 1
  75. Paul, 2017, Intra nasal in situ gelling system of lamotrigine using ion activated mucoadhesive polymer, Open Med. Chem. J., 11, 222, 10.2174/1874104501711010222 · DOI
  76. Agrawal, 2020, Stimuli-responsive in situ gelling system for nose-to-brain drug delivery, J. Contr. Release, 327, 235, 10.1016/j.jconrel.2020.07.044 · DOI
  77. Bialik, 2021, Achievements in thermosensitive gelling systems for rectal administration, Int. J. Mol. Sci., 22, 10.3390/ijms22115500 · DOI
  78. Kouchak, 2014, In situ gelling systems for drug delivery, Jundishapur J. Nat. Pharm. Prod., 9, 10.17795/jjnpp-20126 · DOI
  79. Dash, 2021, Injectable in situ gelling delivery system for the treatment of jawbone infections, Ther. Deliv., 12, 775, 10.4155/tde-2021-0054 · DOI
  80. Singh, 2012, Injectable in-situ gelling controlled release drug delivery system, Int. J. Drug Dev. Res., 4, 56
  81. Khudiyev, 2017, Electrostrictive microelectromechanical fibres and textiles, Nat. Commun., 8, 1435, 10.1038/s41467-017-01558-5 · DOI
  82. Koch, 2016, vol. 9
  83. Chirra, 2012, Multi-reservoir bioadhesive microdevices for independent rate-controlled delivery of multiple drugs, Small, 8, 3839, 10.1002/smll.201201367 · DOI
  84. Ortigoza-Diaz, 2018, Techniques and considerations in the microfabrication of parylene C microelectromechanical systems, Micromachines, 9, 10.3390/mi9090422 · DOI
  85. Ziaie, 2004, Hard and soft micromachining for BioMEMS: review of techniques and examples of applications in microfluidics and drug delivery, Adv. Drug Deliv. Rev., 56, 145, 10.1016/j.addr.2003.09.001 · DOI
  86. Cobo, 2015, MEMS: enabled drug delivery systems, Adv. Healthc. Mater., 4, 969, 10.1002/adhm.201400772 · DOI
  87. Zhang, 2017, Microfabricated drug delivery devices: design, fabrication, and applications, Adv. Funct. Mater., 27, 10.1002/adfm.201703606 · DOI
  88. Song, 2013, An electrochemically actuated MEMS device for individualized drug delivery: an in vitro study, Adv. Healthc. Mater., 2, 1170, 10.1002/adhm.201200356 · DOI
  89. Oh, 2006, A review of microvalves, J. Micromech. Microeng., 16, R13, 10.1088/0960-1317/16/5/R01 · DOI
  90. Sutradhar, 2016, Implantable microchip: the futuristic controlled drug delivery system, Drug Deliv., 23, 1, 10.3109/10717544.2014.903579 · DOI
  91. Kuo, 2012, Micromachined thermal flow sensors—a review, Micromachines, 3, 550, 10.3390/mi3030550 · DOI
  92. Pons-Faudoa, 2019, Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases, Biomed. Microdevices, 21, 47, 10.1007/s10544-019-0389-6 · DOI
  93. Staples, 2010, Microchips and controlled-release drug reservoirs, WIREs Nanomedicine and Nanobiotechnology, 2, 400, 10.1002/wnan.93 · DOI
  94. Hilt, 2005, Microfabricated drug delivery devices, Int. J. Pharm., 306, 15, 10.1016/j.ijpharm.2005.09.022 · DOI
  95. Zamora-Mora, 2017, Chitosan nanoparticles for combined drug delivery and magnetic hyperthermia: from preparation to in vitro studies, Carbohydr, Polym, 157, 361
  96. Silva, 2021, Combined method to remove endotoxins from protein nanocages for drug delivery applications: the case of human ferritin, Pharmaceutics, 13, 10.3390/pharmaceutics13020229 · DOI
  97. Pang, 2017, A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles, Drug Deliv., 24, 83, 10.1080/10717544.2016.1230903 · DOI
  98. Rani, 2014, A review on targeted drug delivery: its entire focus on advanced therapeutics and diagnostics, Scholars J. Appl. Med. Sci., 2, 328
  99. Murugan, 2016, Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy, Sci. Rep., 6
  100. Wu, 2017, Synthesis and in vitro evaluation of pH-sensitive magnetic nanocomposites as methotrexate delivery system for targeted cancer therapy, Mater. Sci. Eng. C. Mater. Biol. Appl., 71, 132, 10.1016/j.msec.2016.09.084 · DOI
  101. Lin, 2015, Tumor-targeted co-delivery of mitomycin C and 10-hydroxycamptothecin via micellar nanocarriers for enhanced anticancer efficacy, RSC Adv., 5, 23022, 10.1039/C4RA14602F · DOI
  102. Xia, 2019, Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application, Acta Pharm. Sin. B., 9, 675, 10.1016/j.apsb.2019.01.011 · DOI
  103. Simone, 2015, Caution should be used in long-term treatment with oral compounds of hyaluronic acid in patients with a history of cancer, Clin. Drug Invest., 35, 689, 10.1007/s40261-015-0339-x · DOI
  104. Hadinoto, 2013, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Fur Pharm. Verfahrenstechnik e.V., 85, 427
  105. Sivadasan, 2021, Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform-A comprehensive review of their properties, preparation methods, and therapeutic applications, Pharmaceutics, 13, 10.3390/pharmaceutics13081291 · DOI
  106. Kumar, 2010, Self emulsifying drug delivery system (SEDDS), Future Aspects, 2
  107. Mishra, 2021, Orally administered self-emulsifying drug delivery system in disease management: advancement and patents, Expert Opin. Drug Deliv., 18, 315, 10.1080/17425247.2021.1856073 · DOI
  108. Shenfield, 1982, Fixed combination drug therapy, Drugs, 23, 462, 10.2165/00003495-198223060-00003 · DOI
  109. Chen, 2012, Limitations and niches of the active targeting approach for nanoparticle drug delivery, 4, 89
  110. Youn, 2018, Perspectives on the past, present, and future of cancer nanomedicine, Adv. Drug Deliv. Rev., 130, 3, 10.1016/j.addr.2018.05.008 · DOI
  111. Pasut, 2019, Grand challenges in nano-based drug delivery, Front. Med. Technol., 1, 10, 10.3389/fmedt.2019.00001 · DOI
  112. Sharma, 2021, Toxicology of nanoparticles in drug delivery, Curr. Pathobiol. Rep., 9, 133, 10.1007/s40139-021-00227-z · DOI
  113. Khalid, 2018, HHS Public Access, 14, 865
  114. Zargar, 2019, A review of controlled drug delivery systems based on cells and cell membranes, J. Med. Signals Sens., 9, 181, 10.4103/jmss.JMSS_53_18 · DOI
  115. Gautami, 2015, Research and Reviews: Journal of Pharmaceutics and Nanotechnology IMPLANTABLE DRUG DELIVERY SYSTEM, 3, 24
  116. Zare, 2021, Carbon nanotubes: smart drug/gene delivery carriers, Int. J. Nanomed., 16, 1681, 10.2147/IJN.S299448 · DOI
  117. Perepelytsina, 2018, Influence of carbon nanotubes and its derivatives on tumor cells in vitro and biochemical parameters, cellular blood composition in vivo, Nanoscale Res. Lett., 13, 286, 10.1186/s11671-018-2689-9 · DOI
  118. Hafeez, 2021, Challenges towards targeted drug delivery in cancer nanomedicines, Processes, 9, 1527, 10.3390/pr9091527 · DOI
  119. Danaei, 2018, Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems, Pharmaceutics, 10, 1, 10.3390/pharmaceutics10020057 · DOI
  120. Bartucci, 2020, Comparative study of nanoparticle uptake and impact in murine lung, liver and kidney tissue slices, Nanotoxicology, 14, 847, 10.1080/17435390.2020.1771785 · DOI
  121. Pandit, 2016, Twenty-five years of nano-bio-materials: have we revolutionized healthcare?, Nanomedicine (Lond)., 11, 985, 10.2217/nnm.16.42 · DOI
  122. Haider, 2020, Nanoparticles : the Future of Drug Delivery, 38, 1
  123. Adepu, 2021, Controlled drug delivery systems: current status and future directions, Molecules, 26, 10.3390/molecules26195905 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., Nwadike, U. G., Ogbodo, J. O., Umeh, B. U., Ossai, E. C., & Nwanguma, B. C.
Venue
Heliyon
Publisher
Elsevier BV
Published
2023-06
Volume
9
Issue
6
Pages
e17488
ISSN
2405-8440
DOI
10.1016/j.heliyon.2023.e17488
PMC
PMC10320272
Cited by
1,040
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review